Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

被引：22

作者：

Brümmendorf, TH ^{[1
]}

Ersöz, I ^{[1
]}

Hartmann, U ^{[1
]}

Bartolovic, K ^{[1
]}

Balabanov, S ^{[1
]}

Wahl, A ^{[1
]}

Paschka, P ^{[1
]}

Krell, S ^{[1
]}

Lahaye, T ^{[1
]}

Berger, U ^{[1
]}

Gschaidmeier, H ^{[1
]}

Bokemeyer, C ^{[1
]}

Hehlmann, R ^{[1
]}

Dietz, K ^{[1
]}

Lansdorp, PM ^{[1
]}

Kanz, L ^{[1
]}

Hochhaus, A ^{[1
]}

机构：

[1] Univ Tubingen, Med Ctr 2, Dept Hematol & Oncol, D-72076 Tubingen, Germany

来源：

BLOOD | 2003年 / 101卷 / 01期

关键词：

D O I：

10.1182/blood-2002-08-2557

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：375 / 376

页数：2

共 10 条

[1] STRUCTURE AND FUNCTION OF TELOMERES [J].

BLACKBURN, EH .

NATURE, 1991, 350 (6319) :569-573

[2] Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase [J].

Boultwood, J ;

Peniket, A ;

Watkins, F ;

Shepherd, P ;

McGale, P ;

Richards, S ;

Fidler, C ;

Littlewood, TJ ;

Wainscoat, JS .

BLOOD, 2000, 96 (01) :358-361

[3] Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry [J].

Brümmendorf, TH ;

Holyoake, TL ;

Rufer, N ;

Barnett, MJ ;

Schulzer, M ;

Eaves, CJ ;

Eaves, AC ;

Lansdorp, PM .

BLOOD, 2000, 95 (06) :1883-1890

[4]

DELANGE T, 1995, TELOMERES, P265

[5] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].

Druker, BJ ;

Tamura, S ;

Buchdunger, E ;

Ohno, S ;

Segal, GM ;

Fanning, S ;

Zimmermann, J ;

Lydon, NB .

NATURE MEDICINE, 1996, 2 (05) :561-566

[6] Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction [J].

Hochhaus, A ;

Lin, F ;

Reiter, A ;

Skladny, H ;

Mason, PJ ;

vanRhee, F ;

Shepherd, PCA ;

Allan, NC ;

Hehlmann, R ;

Goldman, JM ;

Cross, NCP .

BLOOD, 1996, 87 (04) :1549-1555

[7] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[8] Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood [J].

Rufer, N ;

Brümmendorf, TH ;

Kolvraa, S ;

Bischoff, C ;

Christensen, K ;

Wadsworth, L ;

Schulzer, M ;

Lansdorp, PM .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (02) :157-167

[9] Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study [J].

Sawyers, CL ;

Hochhaus, A ;

Feldman, E ;

Goldman, JM ;

Miller, CB ;

Ottmann, OG ;

Schiffer, CA ;

Talpaz, M ;

Guilhot, F ;

Deininger, MWN ;

Fischer, T ;

O'Brien, SG ;

Stone, RM ;

Gambacorti-Passerini, CB ;

Russell, NH ;

Reiffers, JJ ;

Shea, TC ;

Chapuis, B ;

Coutre, S ;

Tura, S ;

Morra, E ;

Larson, RA ;

Saven, A ;

Peschel, C ;

Gratwohl, A ;

Mandelli, F ;

Ben-Am, M ;

Gathmann, I ;

Capdeville, R ;

Paquette, RL ;

Druker, BJ .

BLOOD, 2002, 99 (10) :3530-3539

[10] Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study [J].

Talpaz, M ;

Silver, RT ;

Druker, BJ ;

Goldman, JM ;

Gambacorti-Passerini, C ;

Guilhot, F ;

Schiffer, CA ;

Fischer, T ;

Deininger, MWN ;

Lennard, AL ;

Hochhaus, A ;

Ottmann, OG ;

Gratwohl, A ;

Baccarani, M ;

Stone, R ;

Tura, S ;

Mahon, FX ;

Fernandes-Reese, S ;

Gathmann, I ;

Capdeville, R ;

Kantarjian, HM ;

Sawyers, CL .

BLOOD, 2002, 99 (06) :1928-1937

← 1 →